Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release
- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie
United States United Kingdom Jorge Capapey Kim Hollander Hyperoxaluria Foundation Global Rare Disease Lead At Alnylam Pharmaceuticals
Source: wiredprnews.com